0001127602-24-015293.txt : 20240514
0001127602-24-015293.hdr.sgml : 20240514
20240514171345
ACCESSION NUMBER: 0001127602-24-015293
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240514
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DEKKERS MARIJN E
CENTRAL INDEX KEY: 0001216068
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40097
FILM NUMBER: 24945682
MAIL ADDRESS:
STREET 1: GENERAL ELECTRIC COMPANY
STREET 2: 41 FARNSWORTH STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc.
CENTRAL INDEX KEY: 0001830214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 872652913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (877) 442-5362
MAIL ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20210210
FORMER COMPANY:
FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20201027
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-05-14
0001830214
Ginkgo Bioworks Holdings, Inc.
DNA
0001216068
DEKKERS MARIJN E
C/O GINKGO BIOWORKS HOLDINGS, INC.
27 DRYDOCK AVENUE
BOSTON
MA
02210
1
0
Class A Common Stock
2024-05-14
4
S
0
1727056
.93
D
281217
D
Class A Common Stock
5780364
I
By Novalis LifeSciences Investments I, L.P.
Includes 281,217 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
/s/ Karen Tepichin, Attorney-in-Fact
2024-05-14